#1 Clinical Trials Search in Europe

Leuprorelin

Leuprorelin, also known as leuprolide, is a hormone therapy drug used to treat various conditions. This article examines recent clinical trials investigating leuprorelin’s use and effectiveness for conditions like prostate cancer, breast cancer, uterine fibroids, and other hormone-sensitive disorders. We’ll explore the drug’s mechanisms, administration methods, and potential benefits and side effects as revealed through these studies.

Table of Contents

What is Leuprorelin?

Leuprorelin, also known as leuprolide acetate, is a synthetic hormone medication used to treat various conditions related to hormone imbalances. It belongs to a class of drugs called gonadotropin-releasing hormone (GnRH) agonists[1]. Leuprorelin is available under several brand names, including Leuplin, Enantone, Trenantone, and TAP-144SR[1].

How Does Leuprorelin Work?

Leuprorelin works by mimicking the action of the natural GnRH hormone in the body. Initially, it stimulates the production of certain hormones, but with continuous use, it actually suppresses the production of sex hormones like testosterone and estrogen. This suppression is reversible, meaning hormone levels return to normal after stopping the medication[1].

Conditions Treated with Leuprorelin

Leuprorelin is used to treat several conditions, including:

  • Prostate Cancer: It helps suppress testosterone production, which can slow the growth of prostate cancer cells[2].
  • Breast Cancer: In premenopausal women with hormone-sensitive breast cancer, leuprorelin can be used as part of adjuvant therapy (additional treatment after primary treatment) to suppress estrogen production[3].
  • Uterine Fibroids: Leuprorelin can help reduce the size of uterine fibroids and alleviate associated symptoms[1].
  • Central Precocious Puberty: This is a condition where puberty starts too early in children. Leuprorelin can help pause puberty progression[4].
  • Endometriosis: By suppressing estrogen production, leuprorelin can help manage symptoms of endometriosis[1].
  • Spinal and Bulbar Muscular Atrophy (SBMA): This is a rare genetic disorder affecting motor neurons. Leuprorelin is being studied for its potential benefits in SBMA[5].

How is Leuprorelin Administered?

Leuprorelin is typically administered as a subcutaneous (under the skin) injection. It comes in different formulations:

  • Monthly depot: 3.75 mg injected once every 4 weeks[6].
  • 3-month depot: 11.25 mg injected once every 12 weeks[2].

The specific dosage and frequency may vary depending on the condition being treated and the individual patient’s needs. Always follow your healthcare provider’s instructions for administration.

Effectiveness of Leuprorelin

The effectiveness of leuprorelin can be measured in different ways depending on the condition being treated:

  • For prostate cancer, effectiveness is often measured by the rate of castration (suppression of testosterone) and progression-free survival[2].
  • In breast cancer treatment, researchers look at factors like progression-free survival and overall survival[3].
  • For central precocious puberty, effectiveness is measured by the suppression of hormones like luteinizing hormone (LH) and follicle-stimulating hormone (FSH)[4].

Potential Side Effects

Like all medications, leuprorelin can cause side effects. Some common side effects may include:

  • Hot flashes or sweating
  • Changes in menstrual periods in women
  • Decreased sexual desire or ability
  • Fatigue
  • Headache
  • Mood changes
  • Injection site reactions (pain, redness, or swelling)[7]

It’s important to discuss any side effects you experience with your healthcare provider. They can help determine if the benefits of the treatment outweigh the risks for your specific situation.

Impact on Quality of Life

While leuprorelin can be effective in treating various conditions, it’s also important to consider its impact on quality of life. Some studies have looked at how switching from monthly to 3-monthly injections affects patients:

  • Reduced frequency of medical visits
  • Potential relief from physical and emotional burden due to less frequent injections
  • Possible financial relief due to less frequent treatments
  • Changes in side effects or injection site pain[7]

Your healthcare provider can help you weigh the benefits and potential impacts of leuprorelin treatment on your overall quality of life.

Aspect Details
Main Uses Prostate cancer, breast cancer, uterine fibroids, central precocious puberty, SBMA
Administration Subcutaneous injection, various depot formulations (1-month, 3-month)
Mechanism GnRH agonist, suppresses LH and FSH production
Common Side Effects Menopausal-like symptoms, injection site reactions, hormone level changes
Treatment Duration Varies by condition, ranging from 12 weeks to several years
Efficacy Measures Hormone suppression, tumor response, quality of life improvements
Safety Monitoring Adverse events, serious adverse reactions, long-term effects

FAQ

  • What conditions is leuprorelin used to treat? Based on the clinical trials, leuprorelin is used to treat several conditions including prostate cancer, breast cancer, uterine fibroids, central precocious puberty, and spinal and bulbar muscular atrophy (SBMA).
  • How is leuprorelin typically administered? Leuprorelin is usually administered as a subcutaneous injection. The trials mention various formulations, including 1-month and 3-month depot injections. For example, one study used a 3.75 mg depot injection given every 4 weeks, while another used an 11.25 mg injection given every 12 weeks.
  • What are the main effects of leuprorelin on the body? Leuprorelin acts as a gonadotropin-releasing hormone (GnRH) agonist. It initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), but with continued use, it suppresses their production. This leads to a reduction in sex hormones like testosterone and estrogen.
  • What are some common side effects of leuprorelin? Common side effects mentioned in the trials include menopausal-like symptoms such as hot flushes, injection site reactions, and changes in hormone levels. Some studies also monitored for more serious adverse events, though these were generally less common.
  • How long do patients typically use leuprorelin in treatment? The duration of leuprorelin treatment varies depending on the condition being treated. Some trials lasted 12 weeks, while others continued for up to 96 weeks or even 8 years for long-term safety studies. The appropriate duration would be determined by a healthcare provider based on the specific condition and individual patient factors.

Ongoing Clinical Trials on Leuprorelin

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • Study on Oxybutynin and Venlafaxine for Reducing Hot Flashes in Women Undergoing Endocrine Therapy After Breast Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Shortened Treatment with Apalutamide and Enzalutamide for Patients with Low-Volume Metastatic Castration-Sensitive Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Finland France Germany Greece +7

  • Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia France Germany +8

  • Study on Estradiol and Exercise to Reduce Side Effects of Androgen Deprivation Therapy in Prostate Cancer Patients

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on Docetaxel and Carboplatin-Docetaxel Combination for Prostate Cancer Patients Progressing After Olaparib Treatment

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Palbociclib and Drug Combination for Patients with Hormone Receptor Positive, HER2-Positive Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Portugal Spain

  • Study of [177Lu]Lu-NeoB and Capecitabine for Patients with Advanced Breast Cancer Resistant to Hormone Therapy

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Portugal Spain

  • Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France

Glossary

  • Gonadotropin-releasing hormone (GnRH): A hormone released by the hypothalamus that stimulates the pituitary gland to produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
  • Luteinizing hormone (LH): A hormone produced by the pituitary gland that stimulates ovulation in females and testosterone production in males.
  • Follicle-stimulating hormone (FSH): A hormone produced by the pituitary gland that stimulates the growth of ovarian follicles in females and sperm production in males.
  • Depot injection: A form of injection that deposits the medication into fatty tissue, allowing it to be slowly released over time.
  • Subcutaneous: Beneath the skin. Subcutaneous injections are given into the fatty tissue just under the skin.
  • Estrogen receptor: A protein found on cells that binds to estrogen, allowing the hormone to have effects on the cell.
  • Testosterone suppression: The reduction of testosterone levels in the body, often used as a treatment for prostate cancer.
  • Central precocious puberty: A condition where puberty begins at an unusually early age due to the early activation of the body's hormonal changes.
  • Uterine fibroids: Non-cancerous growths that develop in the uterus, often causing symptoms like heavy menstrual bleeding and pelvic pain.
  • Spinal and bulbar muscular atrophy (SBMA): A genetic disorder that primarily affects males, causing muscle weakness and wasting due to the degeneration of motor neurons.

References

  1. https://clinicaltrials.gov/study/NCT00776074
  2. https://clinicaltrials.gov/study/NCT02167893
  3. https://clinicaltrials.gov/study/NCT02154139
  4. https://clinicaltrials.gov/study/NCT03316482
  5. https://clinicaltrials.gov/study/NCT03555578
  6. https://clinicaltrials.gov/study/NCT03662958
  7. https://clinicaltrials.gov/study/NCT02134977